Our Partners

At the heart of Open Targets is a consortium of complementary partner institutions that bring their respective expertise to collaborative projects that improve how we systematically identify and prioritise drug targets.

News

Graphic describing the project

Study of millions of cells reveals new way to understand genetic risk of disease

3 June 2026

Scientists have created the most detailed cell map to date showing how genetic variation influences inflammatory bowel disease (IBD), revealing the specific cells and genes that drive the disease.

Published today (3 June) in Nature, the research carried out at the Wellcome Sanger Institute, Open Targets, and Cambridge University Hospitals NHS Foundation Trust (CUH), identifies the key genetic and cellular drivers of IBD risk and demonstrates the power of single-cell approaches to u...

Read more

Read more news about Open Targets

Our Principles

A systematic approach

Systematically identify and prioritise the best targets to safely and effectively treat rare and common diseases

Our scientific approach
Open Exchange of Ideas

We are committed to making our data, methods and results publicly available as soon as possible to foster an open exchange of ideas

Our latest publications
Multidisciplinary collaboration

We believe in non-exclusive partnerships that foster the free exchange of ideas, expertise, and data

Our partners and collaborators

Blog

Bluesky